125 related articles for article (PubMed ID: 20061692)
21. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
22. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.
Bjerner J; Høgetveit A; Wold Akselberg K; Vangsnes K; Paus E; Bjøro T; Børmer OP; Nustad K
Scand J Clin Lab Invest; 2008; 68(8):703-13. PubMed ID: 18609108
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of tumour markers in molar pregnancy.
Hegab HM; Schindler AE; Rizk M; Ramadan M
Arch Gynecol Obstet; 2003 Aug; 268(3):151-4. PubMed ID: 12942241
[TBL] [Abstract][Full Text] [Related]
24. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
26. Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency.
Symeonidis A; Kouraklis-Symeonidis A; Apostolopoulos D; Arvanitopoulou E; Giannakoulas N; Vassilakos P; Zoumbos N
Oncology; 2004; 67(5-6):359-67. PubMed ID: 15713991
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
Sütterlin M; Bussen S; Trott S; Caffier H
Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
[TBL] [Abstract][Full Text] [Related]
28. [Dimorphous cancer of the lung].
Briusov PG; Leonova VV
Vopr Onkol; 1997; 43(2):205-7. PubMed ID: 9214124
[TBL] [Abstract][Full Text] [Related]
29. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied.
Espinosa M; Martin-Malo A; Alvarez de Lara MA; Soriano S; Aljama P
Clin Nephrol; 2000 Aug; 54(2):151-6. PubMed ID: 10968693
[TBL] [Abstract][Full Text] [Related]
30. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
31. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
33. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer.
Lumachi F; Basso SM; Bonamini M; Marzano B; Milan E; Waclaw BU; Chiara GB
Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388
[TBL] [Abstract][Full Text] [Related]
34. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
36. [Infection of hepatitis C virus in patients with chronic renal failure undergoing hemodialysis therapy and staff members].
Miyasaka M
Nihon Jinzo Gakkai Shi; 1991 Oct; 33(10):989-99. PubMed ID: 1722830
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
Sevinc A; Buyukberber S; Sari R; Kiroglu Y; Turk HM; Ates M
Gynecol Oncol; 2000 May; 77(2):254-7. PubMed ID: 10785474
[TBL] [Abstract][Full Text] [Related]
38. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
39. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals.
Erden G; Barazi AO; Tezcan G; Yildirimkaya MM
Scand J Clin Lab Invest; 2008; 68(3):212-8. PubMed ID: 17926198
[TBL] [Abstract][Full Text] [Related]
40. Serum tumor markers in hemodialysis patients.
Maoujoud O; El Machtani S; Asseraji M; Atbib Y; Zajjari Y; Taoufik A; Elbouaiti E; Zouhair O; Benyahia M; Tellal S
Int J Artif Organs; 2014 Feb; 37(2):126-32. PubMed ID: 24619900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]